Abstract Number: PB1798
Meeting: ISTH 2020 Congress
Background: Elevated platelet counts may be caused by two conditions. One is reactive thrombosis which is due to infection or inflammation. The other is caused by essential thrombocytosis which is one type of myeloproliferative neoplasm. Janus kinase 2 (JAK2) V617F mutation was found in around 50% of essential thrombosis patients. Several studies have showed that hemogram was changed in patients with JAK2 mutation. JAK2 V617F induced abnormal activation of thrombopoietin receptor (TPOR) and granulocyte colony-stimulating factor (G-CSFR) pathway, leading to hyperplasia of megakaryocytic progenitor cells.
Aims: We hypothesis that JAK2 V617F mutation may influence platelet proliferative and showed differences in platelet parameters, including platelet count, mean platelet volume (MPV) and platelet distribution width (PDW).
Methods: This retrospective study was approved by IRB, and was conducted for patients visiting our hospital (Hualien Tzu Chi Hospital, Taiwan) from 2010 to 2019. All patients had thrombocytosis (more than 400,000/uL) and JAK2 V617F mutation was detected by allele specific real-time quantitative fluorescence PCR. The platelet parameter, including platelet count, MPV and PDW were record. Data analysis with Mann-Whitney test was performed using GraphPad Prism (Version 7). A p-value of <0.05 was considered significant.
Results: 58 patients with ET, including 37 with JAK2 positive and 21 with JAK2 negative and 58 patient with reactive thrombocytosis (all with JAK2 negative) were enrolled in this study. JAK2 V617F mutated ET patients are older (67, 55, vs 55 years old), and had higher platelet count (968,000, 829,000, vs 614,000/uL), larger size (high MPV, 9.8, 9.1, vs 8.8fL), and higher PDW (11.5, 9.8, vs 9.3). All platelet parameters had significant difference. The data showed as table and figure.
Conclusions: The higher platelet count, MPV and PDW were found in essential thrombocytosis patients with JAK2 V617F mutation than JAK2-negative and reactive thrombocytosis.
[Figure. Platelet count, MPV and PDW in ET with JAK2+, JAK2-, and reactive thrombocytosis]
|N||Age (years old)||PLT count (/uL)||MPV (fL)||PDW|
[Table. platelet counts, MPV, and PDW in three groups]
To cite this abstract in AMA style:Wu Y, Gu M, Lin S, Huang W, Wang T, Chu S. Comparison of Platelet Parameters in the Patients with JAK2 V617F Mutated Essential Thrombocytosis and Reactive Thrombocytosis [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/comparison-of-platelet-parameters-in-the-patients-with-jak2-v617f-mutated-essential-thrombocytosis-and-reactive-thrombocytosis/. Accessed January 27, 2022.
« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/comparison-of-platelet-parameters-in-the-patients-with-jak2-v617f-mutated-essential-thrombocytosis-and-reactive-thrombocytosis/